Year: 2025

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Written by Customer Service on November 6, 2025. Posted in Earnings Releases And Operating Results.

FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2025, and provided an update on key corporate milestones and accomplishments. “Lexicon ushered in 2025 with an ambitious slate of objectives embracing and driving our renewed R&D focus,”...

Kelly Reports Third-Quarter 2025 Earnings

Written by Customer Service on November 6, 2025. Posted in Earnings Releases And Operating Results.

TROY, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the third quarter of 2025.Q3 revenue of $935.0 million, down 9.9% year-over-year; excluding discrete U.S. federal government and large customer impacts, underlying revenue down approximately 2.0% year-over-year Underlying revenue reflects continued growth in the Education segment, a consistent rate of decline in the SET segment, and a modest decline in the ETM segment Q3 adjusted SG&A decline of 9.7% reflects increased momentum on structural and demand-driven expense optimization initiatives, including legacy acquisition integration, technology modernization, and process efficiencies Q3 operating loss of $102.1 million including $102.0 million of non-cash goodwill impairment...

Knight Therapeutics Reports Third Quarter 2025 Results

Written by Customer Service on November 6, 2025. Posted in Earnings Releases And Operating Results.

Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q3-25 Highlights Financial resultsRevenues were $121,548, an increase of $29,285 or 32% over the same period in prior year. The increase was primarily driven by the incremental revenues from the Paladin and Sumitomo Transactions and the growth of our key promoted products. Gross margin was $55,810 or 46%...

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Written by Customer Service on November 6, 2025. Posted in Earnings Releases And Operating Results.

IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the third quarter ended September 30, 2025, and recent business highlights. “We have made exciting progress during 2025 advancing our pipeline of next generation therapeutics for solid tumors toward the clinic,” said Joshua Brumm, chief executive officer of Crescent. “For CR-001, our PD-1 x VEGF bispecific antibody,...

Cronos Group Reports 2025 Third Quarter Results

Written by Customer Service on November 6, 2025. Posted in Earnings Releases And Operating Results.

Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDA Net revenue in Q3 2025 increased by 9% quarter-over-quarter and 6% year-over-year Generated record-high net revenue in Israel, where PEACE NATURALS® remains the number one cannabis brand1 Industry-leading balance sheet with $824 million in total cash and cash equivalents and short-term investments TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2025 third quarter business results. “Our third quarter results reflect continued progress towards our objectives, with the business reaching record levels of net revenue, gross profit and adjusted EBITDA generation, driven by the seventh consecutive quarter of record net revenue at Cronos Israel, as well as by continued...

Parker Reports Fiscal 2026 First Quarter Results

Written by Customer Service on November 6, 2025. Posted in Earnings Releases And Operating Results.

Organic Sales and Margin Expansion Drive EPS Growth, FY26 Outlook Increased CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the quarter ended September 30, 2025, that included the following highlights (compared with the prior year period): Fiscal 2026 First Quarter Highlights:Sales were a record $5.1 billion; organic sales growth was 5% Net income was $808 million, an increase of 16%, or $927 million adjusted, an increase of 14% EPS were $6.29, an increase of 18%, or a record $7.22 adjusted, an increase of 16% Segment operating margin was 24.2%, an increase of 160 bps, or 27.4% adjusted, an increase of 170 bps Cash flow from operations was $782 million or 15.4% of sales Repurchased $475 million of shares“Our...

TerrAscend Reports Third Quarter 2025 Financial Results

Written by Customer Service on November 6, 2025. Posted in Earnings Releases And Operating Results.

Net Revenue of $65.1 million Gross Profit Margin of 52.1% from continuing operations, up 110 basis points from 51.0% in the third quarter of 2024 Net Cash provided from continuing operations of $7.1 million and Free Cash Flow¹ of $4.9 million 13th consecutive quarter of positive Cash Flow from continuing operations and 9th consecutive quarter of positive Free Cash Flow¹ During the quarter, completed a $79 million non-dilutive refinancing of existing debt with an additional uncommitted term loan facility of up to $35 million for strategic M&A TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the third quarter ended September 30, 2025. All amounts are...

Exodus Movement, Inc. October 2025 Treasury Update and Monthly Metrics

Written by Customer Service on November 6, 2025. Posted in Public Companies.

Q3 earnings call premarket Nov. 10; Treasury grows to 2,147 BTC OMAHA, Neb., Nov. 06, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or “the company”), a leading self-custodial cryptocurrency platform, today announced an update to selected digital asset holdings of Exodus’ corporate treasury, as well as updated user and exchange provider processed volume metrics, as of October 31, 2025: Selected Digital Asset Holdings (Unaudited)Selected Digital Asset Holdings (Unaudited) Bitcoin (BTC): 2,147 BTC as of October 31, 2025 compared to 2,123 as of September 30, 2025 Ethereum (ETH): 2,784 ETH as of October 31, 2025 compared to 2,770 as of September 30, 2025 Solana (SOL): 49,567 SOL as of October 31, 2025 compared to 47,502 as of September 30, 2025 UsersMonthly Active Users (MAUs): 1.6 million...

Man Group PLC : Form 8.3 – Bluefield Solar Income Fund Ltd

Written by Customer Service on November 6, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Bluefield Solar Income Fund Limited(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For...

Diginex Announces Non-Binding MOU for the Acquisition of Kindred OS and entering the Edge AI Technology market

Written by Customer Service on November 6, 2025. Posted in Mergers And Acquisitions.

The proposed acquisition of Kindred OS will enhance Diginex’s position in the rapidly converging fields of AI, data privacy, ESG, and regulatory compliance technology LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) — Diginex Limited (“Diginex” or the “Company”) (NASDAQ: DGNX), a recognized provider of Sustainability RegTech announces the execution of a non-binding memorandum of understanding (the “MOU”) to acquire Kindred OS (“Kindred”), an innovator in Edge Artificial Intelligence (Edge AI), a technology that enables AI models to run locally, securely, and independently of the cloud. While much of the AI industry is racing toward large, cloud-based AI models, Diginex hopes to chart a different path, one centered on privacy, energy efficiency, and regulatory trust. Edge AI empowers organizations to perform complex data analysis within their...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals